Chronic THC Altered Shared Cerebellar Signaling Beyond CB1 in Mice
Long-term THC treatment disrupted more than CB1-mediated signaling in mouse cerebellum. Responses controlled by adenosine A1 and GABAB receptors also weakened at one downstream enzyme, even though their measured G protein activation remained unchanged.
Two signaling levels were compared
The researchers examined receptor-driven G protein activation and inhibition of adenylyl cyclase in cerebellar tissue. These steps are connected, but they are not identical measurements. CB1, adenosine A1 and GABAB receptors can converge on inhibitory signaling pathways relevant to motor function.
The adaptations did not occur everywhere equally
Prolonged THC produced CB1 downregulation and reduced cannabinoid-driven G protein activation and adenylyl cyclase inhibition. In contrast, G protein activation through A1 or GABAB receptors was unaffected. Nevertheless, those receptors became less effective at inhibiting adenylyl cyclase. Absolute basal and forskolin- or Gs-stimulated enzyme activity did not change.
A possible cross-tolerance mechanism, not a human prediction
The authors proposed that altered inhibitory control of the enzyme could contribute to cross-tolerance for motor-incoordination effects. The study does not establish that every downstream response becomes tolerant or that adenosine and GABA receptor functions are globally impaired. Its evidence comes from mouse cerebellar measurements following controlled THC exposure.
This experiment shows why a receptor-level result can miss adaptation farther downstream. For an assessment of cannabis tolerance, identifying which signaling step changed is more informative than saying simply that a receptor did or did not desensitize. The findings provide no individual test of driving ability.
Related: interpreting cannabis tolerance claims.
Research cited
Selley DE; Cassidy MP; Martin BR; Sim-Selley LJ. Long-term administration of Delta9-tetrahydrocannabinol desensitizes CB1-, adenosine A1-, and GABAB-mediated inhibition of adenylyl cyclase in mouse cerebellum. Molecular pharmacology (2004). doi:10.1124/mol.104.000604. Findings discussed from the study abstract.
